*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

常茂生物化學工程股份有限公司

**Changmao Biochemical Engineering Company Limited***

*(a joint stock limited company incorporated in the People's Republic of China)*

(Stock Code: 954)

# SUPPLEMENTAL ANNOUNCEMENT

# DELAY IN DESPATCH OF THE CIRCULAR IN RELATION TO MAJOR TRANSACTION

# SALE AND LEASEBACK ARRANGEMENT

Reference is made to the announcement dated 30 June 2025 issued by the Company in relation to the Sale and Leaseback Arrangement (the "**Announcement**") and the announcement dated 22 July 2025 issued by the Company in relation to the delay in despatch of the circular in relation to the Sale and Leaseback Arrangement. Unless the context requires otherwise, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Board would like to supplement that the Company has applied and the Stock Exchange has agreed to grant the waiver from strict compliance with Rule 14.41(a) of the Listing Rules on the condition that the Company will despatch the circular on or before 12 August 2025.

*By order of the Board*
**Changmao Biochemical Engineering Company Limited***
**Rui Xin Sheng**
*Chairman*

The PRC, 23 July 2025

*As at the date hereof, Mr. Rui Xin Sheng (Chairman), Pan Chun and Ms. Rui Xiao Qian are the executive Directors, Mr. Yu Xiao Ping, Ms. Leng Yi Xin and Mr. Lin Ze Yu are the non-executive Directors, Mr. Zhou Zhi Wei, Mr. Shu Rong Xin and Ms. Cheng Mun Wah are the independent non-executive Directors.*

**For identification purpose*